[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abdominal-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abdominal-neoplasm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,66,91,157,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100532420","keyscope-study-in-uganda-100532420",false,"NCT06212570","KeyScope Study in Uganda","KeyScope: First-In-Human Clinical Study for Cancer Diagnosis in Uganda","Inclusion Criteria:\n\n* diagnosis of intra-abdominal mass suspicious for cancer\n* body mass index (BMI) of 18-30\n* weight 20-100kg\n* biopsy necessary to determine cancer diagnosis and classify pathology\n* surgeon determine that laproscopic biopsy it technically appropriate\n\nExclusion Criteria:\n\n* significant comorbidities\n* previous major abdominal surgery\n* current pregnancy","ALL",{"count":18,"type":19},12,"ESTIMATED","INTERVENTIONAL",[22],"NA","KeyScope and KeyLoop (collectively called KeySuite) are laparoscopic prototypes that the investigators have designed for the resources, needs and challenges of low- and middle- income countries (LMICs). KeyScope is a laparoscope that plugs into a laptop computer to display images during surgery. It links to a telementoring application so that experienced surgeons can mentor surgeons in capacity-building partnerships. KeyLoop is a laparoscopic retractor that lifts the abdominal wall during surgery, obviating the need for a constant power supply and medical-grade carbon dioxide.\n\nThe investigators will perform a clinical First-in-Human study at the Uganda Cancer Institute. Ugandan surgeons will use the KeySuite devices to perform biopsies of intra-abdominal tumors.",[25],"Abdominal Neoplasm","NOT_YET_RECRUITING","2026-06-01",{"date":29,"type":30},"2026-06-03","ACTUAL",{"date":32,"type":19},"2026-07-01",{"date":34,"type":19},"2028-06-30",{"name":36,"class":37},"Duke University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100640485","postoperative-gi-dysfunction-and-nutrition-in-malnourished-cancer-surgery-patients-100640485","NCT07622888","Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients","Gastrointestinal Dysfunction, Nutritional Status, and Delirium in the Early Postoperative Period in Oncologic Surgical Patients With Pre-existing Malnutrition: A Prospective Two-Center Observational Cohort Study","GIDNUT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed malignant tumor of the abdomen or pelvis with planned radical or cytoreductive surgery.\n* Baseline malnutrition defined as NRS2002 ≥ 3 and at least one phenotypic and one etiologic GLIM criterion.\n* Expected postoperative hospitalization ≥ 7 days.\n* Ability to undergo baseline cognitive and nutritional assessments (MoCA, NRS2002, GLIM, PG-SGA) prior to surgery.\n* Signed informed consent for participation and data collection.\n\nExclusion Criteria:\n\n* Severe decompensated hepatic or renal failure rendering surgery infeasible.\n* Documented preexisting severe cognitive impairment or dementia precluding valid postoperative cognitive\u002Fdelirium assessment (e.g., MoCA \\\u003C 18 or documented dementia).\n* Pregnancy or breastfeeding.\n* Participation in another interventional randomized clinical trial within the prior 30 days that could confound outcomes.\n* Inability to ensure postoperative follow-up or reliable data collection (planned transfer without access, loss of contact).","18 Years",{"count":49,"type":19},120,"OBSERVATIONAL","This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and\u002For pelvic oncologic surgery with pre-existing malnutrition. The study describes the course of postoperative gastrointestinal dysfunction and evaluates whether real-world exposure to parenteral serotonin as part of routine postoperative care is associated with a higher proportion of patients whose gastrointestinal dysfunction regresses to LIFE score less than or equal to 1 by postoperative day 5 (plus or minus 1 day), compared with patients not exposed to serotonin.\n\nAll treatment decisions, including the use of parenteral serotonin, metoclopramide, neostigmine, nutritional support, and other postoperative management, are made solely by the treating physicians in accordance with routine clinical practice. The protocol does not assign, randomize, require, or restrict any drug treatment; it records real-world care, daily LIFE assessments during postoperative days 1 through 7, nutritional status measures, body composition where available, delirium screening, complications, length of stay, and mortality.",[53,54,55,25,56],"Gastrointestinal Dysfunction","Malnutrition","Delirium - Postoperative","Pelvic Neoplasm","2026-05-31",{"date":29,"type":30},{"date":60,"type":19},"2026-10-01",{"date":62,"type":19},"2029-03-01",{"name":64,"class":65},"Arma Ltd.","INDUSTRY",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":47,"enrollmentInfo":75,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":38},"100601693","pediatric-intravenous-contrast-enhanced-ultrasoundceus-in-china-100601693","NCT07113808","Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China","Clinical Medical Quality Control Management of Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China: A Multi-Center Study","CEUS","Inclusion Criteria:\n\n1. Age 29 days to 18 years old;\n2. The clinical diagnosis was abdominal space-occupying lesions, blunt abdominal trauma, ascites of unknown cause, and children with suspected abdominal disease but other examinations could not identify the cause.\n\nExclusion Criteria:\n\n1. Allergic to sulfur hexafluoride or other components;\n2. Heart disease with right-to-left shunt\u002Fsevere pulmonary hypertension \u002Funcontrolled systemic hypertension\u002Frespiratory failure\u002Fheart failure\u002Fsevere arrhythmia;\n3. Electrocardiogram, echocardiography or clinical manifestations of myocardial ischemia;\n4. Patients with severe blood system diseases or infectious diseases;\n5. Hypercoagulable state and recent history of thrombosis;\n6. Severe hepatic and renal insufficiency;\n7. Patients with respiratory tract infection or congenital respiratory malformation.","29 Days",{"count":76,"type":19},108,"The goal of this clinical trial is to evaluate the application of intravenous contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses. The main questions it aims to answer are:\n\n* Is intravenous contrast-enhanced ultrasound helpful for the diagnosis of intra-abdominal diseases in children?\n* What medical problems do participants have when participating in intravenous contrast-enhanced ultrasound examination?\n* How can ultrasound doctors conduct intravenous contrast-enhanced ultrasound examinations in a standardized manner? Researchers will performing intravenous contrast-enhanced ultrasound examinations on participants and collecting research subjects to establish a multicenter clinical data database.\n\nParticipants will:\n\n* Perform abdominal ultrasound examination to assess the condition.\n* At least conduct one intravenous contrast-enhanced ultrasound examination. Based on the result of the contrast examination, decide whether to conduct another examination.\n* Keep a diary of their symptoms and therapeutic process in 30 days.",[25,79,80],"Abdominal Injury","Ascites","RECRUITING","2025-12-05",{"date":84,"type":30},"2025-12-08",{"date":86,"type":30},"2024-09-10",{"date":88,"type":19},"2026-09-30",{"name":90,"class":37},"The Children's Hospital of Zhejiang University School of Medicine",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":20,"phases":101,"briefSummary":104,"conditions":105,"keywords":117,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100484789","phase-1-a-study-of-a-selective-t-cell-receptor-tcr-targeting-bifunctional-antibody-fusion-molecule-star0602-in-participants-with-advanced-solid-tumors-100484789","NCT05592626","A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","A Phase 1\u002F2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)","START-001","Inclusion Criteria:\n\n1. Participants must have histologically confirmed solid tumors that are unresectable, locally advanced, or metastatic and for which standard curative therapies do not exist or are no longer effective or have intolerable toxicities. Subjects should not have received more than three lines of prior therapies for their advanced or metastatic diseases.\n2. For Phase 1, participants must have one of the following solid tumors:\n\n   1. High mutational burden (TMB-H)\n   2. Microsatellite Instability (MSI-H)\u002FDNA mismatch repair (dMMR)\n   3. Virally associated tumors\n3. For Phase 2, participants must have one of the following solid tumors:\n\n   1. TMB-H\n   2. MSI-H\u002FdMMR\n   3. CRC (both Ras wild type and mutant)\n   4. Virally associated tumors\n   5. Metastatic triple negative breast cancer\n   6. Platinum-resistant epithelial ovarian cancer\n   7. Metastatic castration-resistance prostate cancer\n   8. Primary stage IV or recurrent non-small cell lung cancer\n   9. Immunogenic solid tumors\n\n   (Other tumor histologies may also be included in Phase 2 as additional data emerge to support their inclusion.)\n4. Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet the following at the time of enrollment:\n\n   * No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids \\> 10 mg prednisone\u002Fday or equivalent);\n   * No concurrent leptomeningeal disease or cord compression.\n\nExclusion Criteria:\n\n1. Participants with a history of known autoimmune disease with exceptions of:\n\n   * Vitiligo;\n   * Psoriasis, atopic dermatitis or other autoimmune skin condition not requiring systemic treatment;\n   * History of Graves' disease, now euthyroid for \\> 4 weeks;\n   * Hypothyroidism managed by thyroid replacement;\n   * Alopecia;\n   * Arthritis managed without systemic therapy beyond oral nonsteroidal anti-inflammatory drugs.\n   * Adrenal insufficiency well controlled on replacement therapy.\n2. Major surgery or traumatic injury within 8 weeks before first dose of study drug.\n3. Unhealed wounds from surgery or injury.\n4. Treatment with \\>10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within 7 days prior to the initiation of study drug. Exceptions may be made for patients who have had allergic reaction to iodinated contrast media. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed.\n5. Clinically significant cardiovascular\u002Fvascular disease, gastrointestinal disorders, inflammatory processes, pulmonary compromises\n6. Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.\n7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.\n8. Participants who are known to be human immunodeficiency virus positive or hepatitis B or C positive and have uncontrolled disease.\n9. Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma locally advanced skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score ≤ 7), resected melanoma in situ, or any malignancy considered to be indolent and never required systemic therapy, with the exception of indolent lymphomas.\n10. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation).\n11. Hepatic metastases unless adequately treated, either locally (e.g., by surgery, radiofrequency ablation, or chemoembolization) or systemically or both, and stable for 3 months.",{"count":100,"type":19},365,[102,103],"PHASE1","PHASE2","This is an open label, multicenter, phase 1\u002F2 study to assess the safety\u002Ftolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.",[106,107,108,109,110,111,112,113,114,115,116,25],"Advanced Solid Tumors","Genital Neoplasm, Female","Urogenital Neoplasms","Lung Neoplasm","Neoplasms by Site","Papillomavirus Infection","Epstein-Barr Virus Infections","Carcinoma","Neoplasms","Vulvar Neoplasms","Vulvar Diseases",[106,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146],"STAR0602","Intravenous","Antineoplastic Agents","T Cell Receptor-targeting","Bifunctional Antibody-Fusion","Specific T Cell Activator","Tumor Mutational Burden (TMB) High","Microsatellite Instability (MSI) High","Virally Associated Malignancies","Checkpoint Inhibitor Resistance","Immunotherapy","Immune Checkpoint Inhibitor Resistance","Head and Neck Cancer","Nasopharyngeal Cancer","Non-small Cell Lung Cancer","Small Cell Lung Cancer","Biliary Cancer","Melanoma","Merkel Cell Carcinoma","Skin Squamous Cell Carcinoma","Skin Basal Cell Carcinoma","Endometrial Cancer","Colorectal Cancer","Small Bowel Cancer","Cervical Cancer","Gastrointestinal Neoplasms","Gastric Cancer","Esophageal Cancer","Bladder Cancer","2025-07-07",{"date":149,"type":30},"2025-07-09",{"date":151,"type":30},"2023-01-04",{"date":153,"type":19},"2026-10",{"name":155,"class":65},"Marengo Therapeutics, Inc.",32,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":16,"minAge":47,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":178},"100563285","a-pan-cancer-screening-and-diagnosis-model-based-on-abdominal-ct-was-established-100563285","NCT06614179","A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established","Inclusion Criteria:\n\n* Patients with abdominal tumors:\n* all patients were pathologically diagnosed with abdominal tumors;\n* The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;\n* All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.\n* Non-tumor population:\n* all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.\n\nExclusion Criteria:\n\n* Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;",true,"75 Years",{"count":166,"type":19},100000,"Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors",[25],"2024-09-25",{"date":171,"type":30},"2024-09-26",{"date":173,"type":30},"2024-07-01",{"date":175,"type":19},"2029-12-31",{"name":177,"class":37},"Xiangdong Cheng",2,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":163,"sex":16,"minAge":47,"maxAge":186,"enrollmentInfo":187,"targetDuration":189,"studyType":50,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100537354","the-linfu-us-registry-in-patients-with-clinical-signs-andor-symptoms-of-disease-100537354","NCT06276738","The LINFU® U.S. Registry in Patients With Clinical Signs and\u002For Symptoms of Disease","The LINFU® U.S. Registry for the Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With Clinical Signs and\u002For Symptoms of Disease","Inclusion Criteria:\n\n* Both males and females will be enrolled and must be at least 18 years of age and under age of 90\n* Patients, who in the opinion of the Investigator, require biopsy to rule out PDAC because they display at least one of the following or both: a) clinical symptoms of PDAC including jaundice, nausea and vomiting, weight loss, abdominal pain, bloating or the feeling of fullness, itchy skin, lower back pain, light-colored, greasy stools, sudden onset type 2 diabetes, etc. b) one or more imaging studies suggestive of PDAC\n* All patients must undergo contemporaneous imaging, either within 90 days before the LINFU® procedure or within 30 days after the procedure, with one or more of the following: EUS± FNA, MRI\u002FMRCP, ERCP, CT or CEUS.\n* Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.\n\nExclusion Criteria:\n\n* Patient under the age of 18 and over the age 90\n* Contraindications to LINFU®\u002FEUS\u002FERCP as determined by study investigators: Patient with uncorrectable coagulopathy; Patient that cannot undergo anesthesia due to cardiopulmonary contraindication as deemed by the anesthesiologist; Unstable medically (cardiopulmonary, neurologic, or cardiovascular status)\n* Patients undergoing EUS or ERCP for a suspected bile duct cancer arising from the intrahepatic or extrahepatic biliary epithelium\n* Patients who are already known to have PDAC by cytologic or histologic evidence\n* Patients with intraductal papillary mucinous neoplasm of the pancreas (IPMN) identified either before the study or during the study through imaging evaluation will be excluded\n* Pregnant females will be excluded\n* Patient that is unable to provide informed consent\n* Patient with known allergy to the microbubble contrast agent or secretin","90 Years",{"count":188,"type":19},1000,"5 Years","Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC.",[192,193,25],"Pancreatic Cancer","Jaundice","2024-05-12",{"date":196,"type":30},"2024-05-14",{"date":198,"type":19},"2024-06-30",{"date":200,"type":19},"2034-05-01",{"name":202,"class":65},"Adenocyte, LLC"]